Hereditary hemorrhagic telangiectasia and danazol.

Abstract

Letters and Corrections15 July 1988Hereditary Hemorrhagic Telangiectasia and DanazolAmin U. Haq, MD, Jonathan Glass, MD, Catherine V. Netchvolodoff, MD, L. Michael Bowen, MDAmin U. Haq, MDSearch for more papers by this author, Jonathan Glass, MDSearch for more papers by this author, Catherine V. Netchvolodoff, MDSearch for more papers by this author, L. Michael Bowen, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-2-171_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease) is characterized by recurrent bleeding episodes, multiple telangiectasias, and familial occurrence. Treatment of this disease is unsatisfactory. Oral estrogen may be very useful in controlling the frequency and severity of epistaxis (1). However, due to the feminizing effects of estrogens, male patients may be reluctant to take the hormones. The authors were recently forced to search for an alternative treatment in a male patient who refused to take estrogen. There was marked improvement of symptoms with danazol, a synthetic weak androgen.A 41-year-old white army veteran had severe anemia; he had a...